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(NSP),	 and	assessed	 rates	of	 re-	infection.	105	HCV	RNA	positive	participants	were	
enrolled	prospectively.	Participants	were	recruited	from	the	 largest	NSP	 in	Dundee	
over	42	months.	94/105	individuals	commenced	treatment.	Genotype	1	(G1)	individu-












HCV	 treatment	 should	be	pursued	alongside	a	 comprehensive	programme	of	harm	
reduction	interventions	to	help	minimize	re-	infection	and	reduce	HCV	transmission.
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1  | INTRODUC TION
The	global	burden	of	hepatitis	C	virus	(HCV)-	related	liver	disease	
continues to rise.1	 In	 2010,	 the	 number	 of	 deaths	 due	 to	 HCV	





In	 2016,	 1.76	million	 of	 the	 71	million	 people	 living	 with	
HCV	 worldwide	 received	 treatment	 (~2.48%	 treatment	 uptake).7 
Treatment	 uptake	 has	 been	 historically	 low	 among	PWID	prior	 to	
the	introduction	of	new	direct-	acting	antivirals	(DAA)	treatments.8 
However,	 there	 is	now	good	evidence	 that	HCV	 treatment	 is	 safe	




Treating	 active	 PWID	 also	 has	 the	 potential	 to	 reduce	 HCV	
transmission,	 a	 concept	 known	 as	 treatment	 as	 prevention	 (TasP).	
Modelling	 data	 suggest	 that	 scaling-	up	 treatment	 among	 current	
PWID	with	DAAs	is	critical	to	reducing	HCV	prevalence,16-18 and is 
F IGURE  1 Flow	diagram	of	cohort	recruitment	into	Eradicate	study
124 HCV antibody positive individuals
newly diagnosed on DBS testing
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drug	 use”	 as	 those	who	 have	 injected	 in	 the	 last	 6	 or	 12	months,	




target	PWID	who	are	most	 likely	 to	 transmit	 the	virus.	This	 is	 the	
study population we aimed to recruit.






2.1 | Study design and cohort recruitment




(range	 1280-	2118	 anonymous	 individuals	 per	 year	 between	 2012	
and	 2016)	were	 offered	 yearly	 dried	 blood	 spot	 testing	 (DBS)	 for	
blood-	borne	viruses	 (BBV)	 (range	123-	203	 identified	PWID	tested	
per	year	2009-	2016).	During	the	study	enrolment	period,	all	PWID	
who	tested	positive	for	HCV	and	fulfilled	study	enrolment	criteria	
(Table	1)	were	 invited	 to	 participate.	Only	 individuals	who	had	 in-
jected	in	the	past	week	were	eligible	for	the	study.	Recruitment	was	
carried	 out	 by	 on-	site	 research	 nurses.	 All	 participants	who	were	
not	already	prescribed	OST	were	offered	low-	threshold	methadone	





Scotland Research Ethics committee.
2.2 | HCV treatment
HCV	 treatment	 followed	 standard	 NHS	 clinical	 practice	 at	 the	
time	 of	 study	 enrolment.	 Individuals	 were	 treated	 with	 peg-	
interferon+ribavirin+/−	protease	inhibitor	for	12,	16	or	24	weeks	
(see	 Appendix	 S1).	 During	 treatment,	 patients	 attended	 weekly	
study	visits	at	the	NSP.	At	each	weekly	visit,	participants	received	
an	interferon	injection	and	a	week’s	supply	of	tablets.	Participants	





















2.4 | Study outcomes and analysis
Three	primary	outcomes	were	assessed:	 (a)	successful	recruitment	
of	our	target	population	into	the	study;	(b)	proportion	who	achieved	
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The	 EQ5D-	5D-	3L	 is	 a	 standardized	 questionnaire	 which	 assesses	
quality	of	life	(QoL)	in	five	dimensions.	It	is	widely	used	to	measure	
health	 states	 among	 this	 population.28,29	 During	 analysis,	 a	 single	






priori23,32	 included	age,	 sex,	on	OST	 treatment,	 length	HCV	treat-
ment,	 incarceration	 during	 treatment,	 homelessness,	 living	 with	
other	 PWID,	 history	 of	 anxiety	 and	 depression	 and	 injecting	 fre-
quency.	 Logistic	 regression	was	 also	 used	 to	 assess	 predictors	 of	
SVR-	12.	Factors	were	based	on	known	predictors	of	SVR-	12	 from	
existing	literature.23,32-34	These	included	treatment	adherence,	age,	
sex,	 fibrosis	 score,	 HCV	 genotype	 and	 pre-	treatment	 HCV	 RNA	









infection	or	date	of	 last	negative	PCR	 test	 (if	 not	 reinfected).	The	




this participant, the time- at- risk period was the mid- point between 
end-	of-	treatment	 and	 SVR-	12.	 Participants	 who	 did	 not	 achieve	
SVR-	12	or	who	died	prior	to	6-	month	PCR	test	were	excluded	from	
estimates	of	 re-	infection.	 Participants	who	were	 lost	 to	 follow-	up	
were	censored	at	the	last	post-	treatment	PCR	test	obtained.	Six	pa-







3.1 | Recruitment and baseline characteristics









34	 (SD	 6.9)	 years;	 the	majority,	 71.3%	 (67/94),	 were	male;	 1	 in	 5	
participants	 were	 homeless	 or	 living	 in	 unstable	 accommodation	
(20/94);	and	12.8%	(12/94)	were	in	prison	at	some	point	during	the	
treatment	period	(Table	2).	Reported	history	of	anxiety/depression	
was	 high,	 69.2%	 (65/94),	 and	 37/94	 (39.4%)	 reported	 a	 previous	
suicide	 attempt.	Median	 injecting	 frequency	was	 6.5	 times/week;	
54.3%	 (51/93)	 participants	 injected	 daily/more	 than	 once	 a	 day.	
Reported	alcohol	consumption	was	comparatively	low:	9.6%	(9/94)	
consumed	alcohol	>3	times	a	week.
Median	health	 utility	was	0.72	 (IQR	0.41-	0.85)	 on	EQ5D,	with	





reported),37	 and	 62.5%	 (55/88)	were	 receiving	 opiate	 substitution	
therapy	 (OST)	 prior	 to	 enrolment	 (with	 a	 further	 11	 participants	
commenced	on	OST	at	enrolment).	39.4%	(37/94)	were	genotype	1	
(G1),	60.6%	(57/94)	genotype	2/3	(G2/3).	Levels	of	significant	fibro-
sis	 (F2-	F4)	were	 low;	17/94	 (18.1%).	All	participants	were	HIV	and	
hepatitis	B	negative.
3.2 | Treatment outcomes







treatment	 due	 to	 deteriorating	mental	 health;	 one	 died	 from	 sus-
pected	drug	overdose.	Of	the	64/94	participants	on	OST	at	enrol-
ment,	 the	 majority,	 93.8%	 (60/64),	 remained	 on	 OST	 during	 the	
treatment	 period.	 All	 participants	 attended	 follow-	up	 at	 6-	month	
     |  5SCHULKIND et aL.
post-	treatment.	 At	 18	months,	 nine	 participants	 had	 been	 lost	 to	
follow-	up	(Figure	2).




5.55/100	 person-	years	 (95%	 CI	 2.77-	11.09)	 during	 treatment	 and	
follow-	up	period	(total	follow-	up	time	144.24	years).
3.3 | Predictors of treatment adherence and SVR- 12
Longer	 treatment	 length	 (24	weeks	 vs	 12/16	weeks)	 was	 associ-
ated	with	reduced	treatment	adherence,	OR	0.35	(95%	CI	0.13-	0.98)	
(P	=	0.047)	(Table	4).	Remaining	on	OST	during	the	study	was	weakly	
associated	with	 increased	 adherence,	OR	2.03	 (95%	CI	 0.82-	5.08)	
(P	=	0.13).	There	was	no	convincing	evidence	of	an	association	be-
tween	adherence	and	other	hypothesized	factors;	age,	sex,	unstable	
housing,	 incarceration,	 living	 with	 other	 drug	 users,	 injecting	 fre-
quency,	history	anxiety/depression.	Therefore,	multivariable	analy-
sis	was	not	performed.
In	 univariable	 analysis,	 a	 greater	 proportion	 of	 treatment	 ad-
herent	 participants	 achieved	 SVR	 (OR	 7.00,	 95%	 CI	 2.24-	21.8,	
P	<	0.001)	 (Appendix	 S3).	 Age,	 sex,	 fibrosis	 level,	 PCR	 RNA	 level	
and	genotype	did	not	 independently	predict	 achievement	of	SVR-	
12.	In	adjusted	analysis,	with	all	variables	from	unadjusted	analysis	
included in model, adherence remained positively correlated with 
achieving	SVR	(P	<	0.001).
3.4 | Re- infection rate
At	 six	months,	 5/77	 participants	 who	 achieved	 SVR-	12	 had	 be-
come	reinfected	yielding	a	re-	infection	rate	of	23.53/100	person-	
years	 (95%	 CI	 9.80-	56.54).	 The	 total	 follow-	up	 time	 was	 21.25	
person-	years.	At	18	months,	 there	were	15/77	re-	infections	giv-
ing	a	cumulative	18-	month	re-	infection	rate	of	21.49/100	person-	
years	 (95%	 CI	 13.00-	35.65)	 over	 total	 follow-	up	 time	 69.79	
person- years.
Unadjusted	 analysis	 found	 age	 <30	years	 was	 weakly	 associ-































































have Fibroscan results. 
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and	 re-	infection.	 Gold	 standard	 would	 be	 sequencing	 to	 confirm	
re-	infection.
4.3 | Comparison to existing literature and 
implications





Genotype G1 G2/3 Total
Study outcome N % n % n %
Genotype 37 39.4 57 60.6 94 100




















17 did not achieve SVR12
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PCR RNA at 12 wks)
2 Died 
1 re-infection
4 new re-infections 
at 6-months
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10 new re-infections at 
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1 Declined PCR test
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1.77/100	pyrs	 to	 2.4/100	pyrs.10,38	 Though	 recent	 studies	 report	
greater	 re-	infection	 rates	 among	 higher	 risk	 populations;	 4.9/100	
person-	years	 among	 relapsed	 PWID39	 to	 5.7/100	 person-	years	
among	individuals	hospitalized	for	a	drug-	related	cause.35	However,	
all these studies10,35,36,38-43	 defined	 “active	 PWID”	 as	 those	 who	
have	“injected	in	the	past	6-	or	12-	months”—except	Hilsden	et	al44 
who	defined	“active”	as	having	injected	in	the	past	3	months,	with	a	





at	 12.4/100	pyrs	 (CI	 6.8-	19.5)	 in	 2015/2016.45	 This	 has	 two	 im-
plications.	 First,	 the	 evidence	 supports	 a	 critical	 assumption	 of	
impact and economic models that there may be no additional be-
haviour	 change	 following	HCV	 treatment	 (over	 and	 above	 expo-
sure	 to	 other	 interventions)	 and	 re-	infection	 rates	 are	 similar	 to	
HCV	incidence	in	the	community.16,17,19	Second,	the	high	HCV	in-
cidence	and	re-	infection	rates	highlight	the	failure	of	current	cov-
erage	 and	 intensity	 of	 harm	 reduction	 interventions	 to	minimize	
injecting	risk.
This	high	re-	infection	rate,	along	with	a	significant	mortality	rate	
(5.55/100	 person-	years)	 and	 high	 level	 of	 incarceration	 (12.8%	 in	
prison	at	some	point	during	study	period),	indicate	this	is	an	unstable	
population	who	would	benefit	from	a	broader	programme	of	social	
and	 psychological	 interventions—alongside	 NSP	 and	 OST	 provi-
sion—to	reduce	injecting	risk,	as	recommended	by	recent	UK	clinical	
guidelines.26	Once	treated,	at-	risk	individuals	should	continue	to	be	
regularly	tested	for	re-	infection	and	retreated	 if	active	 infection	 is	
detected,	as	per	latest	international	guidelines.14	At	the	time	of	writ-
ing	this	paper,	10/15	of	reinfected	participants	are	currently	being	
retreated or have completed retreatment.
SVR-	12	 rates	 are	 higher	 than	 reported	 rates	 among	 PWID	 for	
these	drugs	in	the	literature.10,32	This	may	be	due	to	several	factors.	
The	 study	 population	 is	 on	 average	 younger,	 with	 lower	 fibrosis	
scores	and	 lower	 initial	HCV	RNA	 levels	compared	to	 those	 in	ex-
isting	studies.10,32	These	are	well-	described	factors	associated	with	
higher	 cures	 for	 interferon,	 ribavirin	 and	 first-	generation	protease	
inhibitors.	 Health-	related	 quality	 of	 life	 was	 low,	 in	 keeping	 with	
previous	studies	among	HCV+	populations	and	PWIDs.28,46	Overall,	
treatment	 adherence	was	 71.3%,	 slightly	 lower	 than	 has	 been	 re-
ported in literature.10,32	However,	these	data	remain	impressive	con-
sidering	 this	 is	a	highly	active	 injecting	population	with	significant	
rates	 of	 homelessness,	 incarceration	 and	mental	 health	 problems.	
Weekly	nurse-	led	follow-	up	visits	and	use	of	contingency	manage-
ment	may	have	 influenced	adherence.	The	 results	 add	 to	 growing	
evidence	that	HCV	treatment	can	be	successfully	provided	through	
community- based models.9,10,23,24,44,47
Our	 results	 demonstrate	 some	 association	 between	 OST	 and	





ment	 regimens	 which	 are	 now	 only	 8-	 or	 12-	weeks.	 Re-	infection	
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